Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer

References

• Shahinian VB, Kuo YF, Freeman JL, et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005;103:1615–24
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–9
   PubMed Web of Science ®Google Scholar
• Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103–6
   PubMed Web of Science ®Google Scholar
• Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238–44
   PubMed Web of Science ®Google Scholar
• Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154–79
   PubMed Web of Science ®Google Scholar
• Lebret T, Culine S, Davin JL, et al. Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study. Aging Male 2014;17:87–93
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley A, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2012;104:1518–23
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39–46
   PubMed Web of Science ®Google Scholar
• Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448–56
   PubMed Web of Science ®Google Scholar
• Teoh JY, Chiu PK, Chan SY, et al. Risk of new-onset diabetes after androgen deprivation therapy for prostate cancer in the asian population. J Diabetes 2014. doi: 10.1111/1753-0407.12226. [Epub ahead of print]
   PubMedGoogle Scholar
• Dickman PW, Adolfsson J, Astrom K, Steineck G. Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 2004;172:2208–12
   PubMed Web of Science ®Google Scholar
• Smith MR, Lee WC, Brandman J, et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005;23:7897–903
   PubMed Web of Science ®Google Scholar
• Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154–64
   PubMed Web of Science ®Google Scholar
• Garcia-Fontana B, Morales-Santana S, Varsavsky M, et al. Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporos Int 2014;25:645–51
   PubMed Web of Science ®Google Scholar
• Grossmann M, Cheung AS, Zajac JD. Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Pract Res Clin Endocrinol Metab 2013;27:603–16
   PubMed Web of Science ®Google Scholar
• Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779–86
   PubMed Web of Science ®Google Scholar
• Galvao DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008;102:44–7
   PubMed Web of Science ®Google Scholar
• Hamilton EJ, Ghasem-Zadeh A, Gianatti E, et al. Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 2010;95:E456–63
   PubMed Web of Science ®Google Scholar
• Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005–7
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167:2361–7; discussion 7
   PubMed Web of Science ®Google Scholar
• Wang W, Yuasa T, Tsuchiya N, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer 2008;15:943–52
   PubMed Web of Science ®Google Scholar
• Yuasa T, Maita S, Tsuchiya N, et al. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 2010;75:1131–7
   PubMed Web of Science ®Google Scholar
• Morote J, Morin JP, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 2007;69:500–4
   PubMed Web of Science ®Google Scholar
• Planas Morin J, Morote Robles J. Skeletal complications of ADT: disease burden and treatment options. Asian J Androl 2012;14:670–5
   PubMed Web of Science ®Google Scholar
• Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315–23
   PubMed Web of Science ®Google Scholar
• Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005;8:739–50
   PubMed Web of Science ®Google Scholar
• Wright-St Clair VA, Malcolm W, Keogh JW. The lived experience of physically active older prostate cancer survivors on androgen deprivation therapy. Aging Male 2014;17:57–62
   PubMed Web of Science ®Google Scholar
• Oz SG, Guven GS, Kilicarslan A, et al. Evaluation of bone metabolism and bone mass in patients with type-2 diabetes mellitus. J Natl Med Assoc 2006;98:1598–604
   PubMed Web of Science ®Google Scholar
• Gaudio A, Privitera F, Battaglia K, et al. Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97:3744–50
   PubMed Web of Science ®Google Scholar
• Ardawi MS, Akhbar DH, Alshaikh A, et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 2013;56:355–62
   PubMed Web of Science ®Google Scholar
• Gennari L, Merlotti D, Valenti R, et al. Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012;97:1737–44
   PubMed Web of Science ®Google Scholar
• de Waard EA, van Geel TA, Savelberg HH, et al. Increased fracture risk in patients with type 2 diabetes mellitus: an overview of the underlying mechanisms and the usefulness of imaging modalities and fracture risk assessment tools. Maturitas 2014;79(3):265–74
   PubMed Web of Science ®Google Scholar
• Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008;19:129–37
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Cellai I, Luciani P, et al. Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells. J Endocrinol Invest 2007;30:RC26–30
   PubMed Web of Science ®Google Scholar
• Pluskiewicz W, Adamczyk P, Franek E, et al. FRAX calculator and Garvan nomogram in male osteoporotic population. Aging Male 2014;17:174–82
   PubMed Web of Science ®Google Scholar